Results 11 to 20 of about 8,860 (153)

Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe

BMC Pharmacology and Toxicology, 2021
Background Drug potency is a pharmacological parameter defining dose or concentration of drug required to obtain 50% of the drug’s maximal effect.
Bernard Ngara, Simbarashe Zvada, Tariro Dianah Chawana, Charles Fungai Brian Nhachi, Simbarashe Rusakaniko   +4 more
doaj   +1 more source

Microparticles of Sericin-Dextran Conjugate for Improving the Solubility of Antiviral Drug

Journal of Functional Biomaterials, 2023
A novel sericin-dextran conjugate (SDC) and self-assembled microparticles has been prepared for improving solubility of atazanavir. Microparticles of SDC were assembled by the reprecipitation method. The size and morphology of SDC microparticles could be
Shuqi Chen, Xiaolong Feng, Xinwei Li, Miaochang Liu, Wenxia Gao, Qian Miao, Huayue Wu   +6 more
doaj   +1 more source

UGT1A1 Fragment Analysis: Genotyping the (TA)_n Variable Repeat Polymorphism for Clinical Applications. [PDF]

J Clin Lab Anal
This study developed a PCR‐based fragment analysis assay for UGT1A1 rs3064744 targeting TA5 (*36), TA6 (*1), TA7 (*28), and TA8 (*37). The assay was CLIA validated with data showing 100% concordance and a sensitivity of 0.5 ng/uL. The assay was then implemented in a patient cohort of n = 940 and the results compared with PharmacoScan.
Baugher RN, Pike KM, Plona TM, Mellott SD, Young TB, Lawhorn HE, Hewitt SM.   +6 more
europepmc   +2 more sources

Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study

Journal of Microbiology, Immunology and Infection, 2017
Background/Purpose: Treatment response to switch regimens containing unboosted atazanavir and tenofovir disoproxil fumarate (TDF)/lamivudine guided by therapeutic drug monitoring in human immunodeficiency virus-infected patients is rarely investigated ...
Mao-Song Tsai, Sui-Yuan Chang, Shu-Wen Lin, Ching-Hua Kuo, Hsin-Yun Sun, Bin-Ru Wu, Sue-Yo Tang, Wen-Chun Liu, Yi-Ching Su, Chien-Ching Hung, Shan-Chwen Chang   +10 more
doaj   +1 more source

Effectiveness and Safety of Atazanavir Use for the Treatment of Children and Adolescents Living With HIV: A Systematic Review

Frontiers in Pediatrics, 2022
BackgroundAtazanavir/ritonavir is recommended as a preferred second-line antiretroviral regimen in children older than 3 months, alternatively to lopinavir/ritonavir.
Laura Saint-Lary, Marc Harris Dassi Tchoupa Revegue, Julie Jesson, Françoise Renaud, Martina Penazzato, Claire L. Townsend, John O'Rourke, Valériane Leroy, WHO HIV Hepatitis and STIs (HHS) Department   +8 more
doaj   +1 more source

HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.

PLoS ONE, 2020
ObjectivesAging HIV-infected antiretroviral-treatment (ART)-controlled patients often present cardiovascular and metabolic comorbidities. Thus, it is mandatory that life-long used ART has no cardiometabolic toxicity.
Martine Auclair, Anne-Claire Guénantin, Soraya Fellahi, Marie Garcia, Jacqueline Capeau   +4 more
doaj   +1 more source

Severe Skin Rash Associated with Atazanavir

Canadian Journal of Infectious Diseases and Medical Microbiology, 2009
Three cases of severe rash associated with the use of atazanavir are described. In all cases, the rash was maculopapular and pruritic. Rash onset occurred eight to 11 days after initiation of therapy, and resolved with atazanavir discontinuation ...
Andrew Walkty, Dick Smith, Bernie Lopko, Ken Kasper   +3 more
doaj   +1 more source

Chemical and Toxicological Analysis of Antiretroviral Drugs

Разработка и регистрация лекарственных средств, 2019
Introduction. Human Immunodeficiency Virus (HIV) is one of the main socially significant infection all over the world. HIV-positive patients take medical care, including antiretroviral drugs (ARVs) pharmacotherapy.
T. N. Komarov, M. V. Belova, D. D. Stolyarova, I. E. Shohin, D. S. Bogdanova, O. A. Miskiv, Yu. V. Medvedev, I. M. Korenskaya   +7 more
doaj   +1 more source

The Efficacy and Safety of Adding Chlorpromazine to Atazanavir/Ritonavir Regimen in the Treatment of Moderate COVID-19 Patients, a Randomized Double-blind Clinical Trial [PDF]

Pharmaceutical and Biomedical Research, 2023
Background: According to COVID-19 mutation and no defined treatment, it is necessary to find effective treatment. Chlorpromazine, a phenothiazine antipsychotic drug, has been shown in animal studies to have antiviral effects by inhibiting clathrin ...
Sima Ramezaninejad, Hamid Reza Namvar, Masoumeh Sohrabi, David Darvishnia, Nematollah Ahangar, Ahmad Alikhani, Hamideh Abbaspour, Reza Valadan, Zahra Akbari, Jafar Akbari, Roya Ghasemian, Ebrahim Salehifar   +11 more
doaj  

Evaluation of pharmacokinetic and pharmacodynamic interaction between repaglinide and atazanavir in healthy, diabetic and hepatic impaired rats: possible inhibition of CYP3A, OATP, and P-glycoprotein transporters

ADMET and DMPK, 2016
The metabolic syndrome in HIV infected patients is particularly associated with the use protease inhibitors. Atazanavir is an inhibitor of the cytochrome P 450 (CYP) system, in particular CYP3A4 and CYP2C9 which can affect the metabolism of several drugs.
Thirumal Eswara Goud, Srinivas Maddi, Nayakanti Devanna, Thatipamula Rajendra Prasad   +3 more
doaj   +1 more source